On November 29, 2021 Ranok Therapeutics (Hangzhou) Co. Ltd., an emerging biopharmaceutical company focused on developing breakthrough therapies for cancer and other serious diseases, reported an agreement with Pfizer Inc. to apply and evaluate Ranok’s CHAMP platform technology on an undisclosed cancer target (Press release, Ranok Therapeutics, NOV 29, 2021, View Source [SID1234596212]). Terms of the agreement were not disclosed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ranok has developed a proprietary and innovative targeted protein degradation (TPD) platform technology, CHAMP (Chaperone-mediated Protein Degradation), which leverages Ranok’s founders’ expertise in protein homeostasis to take advantage of the cellular chaperone network, potentially improving drug safety and efficacy due to selective targeting of disease tissues.

"We are very pleased to work with Pfizer to explore the application of CHAMP to an emerging cancer drug target," said Kevin P. Foley, Ph.D., Co-founder and Chief Scientific Officer of Ranok Therapeutics. "This represents our first pharmaceutical company research relationship and is an important step forward in establishing CHAMP as a preferred technology in the rapidly-growing field of targeted protein degradation. We look forward to uncovering new benefits of CHAMP through this research."

This evaluation agreement builds upon Ranok’s recent momentum, including its $40 million Series B financing in August 2021.